2012
Rate of change in carotid intima–media thickness and vascular events
Bots ML, Taylor AJ, Kastelein JJ, Peters SA, Ruijter H, Tegeler CH, Baldassarre D, Stein JH, O’Leary D, Revkin JH, Grobbee DE. Rate of change in carotid intima–media thickness and vascular events. Journal Of Hypertension 2012, 30: 1690-1696. PMID: 22895014, DOI: 10.1097/hjh.0b013e32835644dc.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessIntima-media thicknessFuture cardiovascular disease riskCardiovascular disease riskTherapy-induced changesCardiovascular drug developmentDifferent risk profilesVascular eventsPrimary outcomeVascular riskMeta-regression techniquesHeterogeneous efficacyCardiovascular treatmentPharmaceutical interventionsDisease riskRisk profileDrug developmentTrialsEcologic fallacyTreatmentLack of powerRisk
2007
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, Investigators F. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. The Lancet 2007, 370: 153-160. PMID: 17630038, DOI: 10.1016/s0140-6736(07)61088-5.Peer-Reviewed Original ResearchConceptsIntima-media thicknessMaximum intima-media thicknessCarotid intima-media thicknessDouble-blind trialSystolic blood pressureCombined-treatment groupMixed dyslipidaemiaCholesteryl ester transfer proteinHDL cholesterolLipoprotein cholesterolBlood pressureLDL cholesterolCarotid segmentsHigh low-density lipoprotein cholesterolLow high-density lipoprotein cholesterolMaximum carotid intima-media thicknessHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolCarotid atherosclerosis progressionDose of treatmentYearly rateEster transfer proteinDose titrationPrimary endpointAtherosclerosis progressionEffect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. New England Journal Of Medicine 2007, 356: 1620-1630. PMID: 17387131, DOI: 10.1056/nejmoa071359.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnticholesteremic AgentsAtherosclerosisAtorvastatinCarotid ArteriesCarotid Artery DiseasesCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDLDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationFemaleHeptanoic AcidsHeterozygoteHumansHyperlipoproteinemia Type IIMaleMiddle AgedProspective StudiesPyrrolesQuinolinesConceptsCarotid intima-media thicknessIntima-media thicknessHDL cholesterol levelsCholesterol levelsFamilial hypercholesterolemiaMean low-density lipoprotein cholesterol levelLow-density lipoprotein cholesterol levelsMean carotid intima-media thicknessMaximum carotid intima-media thicknessAverage systolic blood pressureMean HDL cholesterol levelHigh-density lipoprotein cholesterolCarotid arterial wall thicknessCommon carotid segmentEffects of torcetrapibSecondary efficacy measuresLipoprotein cholesterol levelsSystolic blood pressureAtherosclerotic vascular diseaseCommon carotid arteryB-mode ultrasonographyProgression of diseaseArterial wall thicknessCholesteryl ester transfer proteinEster transfer proteinDesigns of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*
Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML. Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*. Current Medical Research And Opinion 2007, 23: 885-894. PMID: 17407645, DOI: 10.1185/030079907x182121.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlgorithmsAnticholesteremic AgentsAtherosclerosisAtorvastatinCarotid ArteriesClinical Trials as TopicDouble-Blind MethodDrug Therapy, CombinationFemaleHeptanoic AcidsHumansHyperlipidemia, Familial CombinedHyperlipoproteinemia Type IIMaleMiddle AgedModels, BiologicalPyrrolesQuinolinesResearch DesignTunica IntimaUltrasonographyConceptsCarotid intima-media thicknessMaximum carotid intima-media thicknessNCEP ATP III guidelinesATP III guidelinesCarotid ultrasound studiesDose of atorvastatinPrimary efficacy measureLDL-C levelsIntima-media thicknessHeterozygous familial hypercholesterolemiaEnd of studyB-mode ultrasonographyFurther outcome measuresRADIANCE studyEligible subjectsControlled TrialsAtherosclerotic progressionEfficacy measuresMixed hyperlipidemiaTreatment periodOutcome measuresUltrasound studyNumber of subjectsFamilial hypercholesterolemiaCarotid segmentsBiomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future. Pharmacological Reviews 2007, 59: 40-53. PMID: 17329547, DOI: 10.1124/pr.59.1.1.Peer-Reviewed Original ResearchConceptsAtherosclerotic progressionClinical trialsCardiovascular diseaseCardiovascular outcomesSurrogate markerCarotid intima-media thicknessIdeal surrogate markerFuture cardiovascular eventsIntima-media thicknessCause of morbidityNew cardiovascular drugsQuantitative coronary angiographyTreatment of atherosclerosisNovel therapeutic strategiesB-mode ultrasoundAtheroma volumeCardiovascular eventsCardiovascular riskCoronary angiographyEffective therapySurrogate endpointsCardiovascular drugsTherapeutic strategiesIntravascular ultrasoundSuch trials
2005
W10-P-004 Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemia
Bots M, Riley W, Evans G, Kastelein J, Revkin J, Thuren T, Shear C, Nguyen T. W10-P-004 Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemia. Atherosclerosis Plus 2005, 6: 48. DOI: 10.1016/s1567-5688(05)80191-6.Peer-Reviewed Original Research